Investors Purchase High Volume of Ocugen Call Options (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN) was the recipient of some unusual options trading on Wednesday. Investors acquired 5,566 call options on the stock. This represents an increase of approximately 62% compared to the average daily volume of 3,429 call options.

Ocugen Stock Up 29.9%

OCGN stock opened at $2.30 on Thursday. Ocugen has a fifty-two week low of $0.52 and a fifty-two week high of $2.37. The company has a market capitalization of $754.16 million, a price-to-earnings ratio of -10.00 and a beta of 2.75. The business’s 50 day moving average price is $1.61 and its two-hundred day moving average price is $1.45. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.06 and a current ratio of 1.06.

Ocugen (NASDAQ:OCGN) last released its earnings results on Wednesday, March 4th. The company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). The company had revenue of ($0.19) million during the quarter, compared to analysts’ expectations of $0.86 million. Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%. As a group, analysts forecast that Ocugen will post -0.2 earnings per share for the current fiscal year.

Ocugen News Roundup

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Oppenheimer initiated coverage at “Outperform” with a $10 price target (implies ~334% upside vs. current levels), bringing fresh institutional attention and a large bullish valuation anchor for the stock. Oppenheimer Starts Ocugen at Outperform
• Positive Sentiment: HC Wainwright raised near‑term EPS estimates for multiple 2026 quarters and lifted FY2026 forecasts slightly, signaling improving analyst outlook on near-term performance and clinical progress. HC Wainwright estimate updates
• Positive Sentiment: Ocugen completed enrollment for its Phase 3 OCU400 gene‑therapy trial — a major clinical milestone that derisks the program timeline and supports future value if readouts are positive. Phase 3 enrollment complete
• Positive Sentiment: Unusually large call buying (≈5,566 calls, ~62% above typical call volume) suggests speculative or directional bullish positioning from options traders, which can amplify upside moves in the underlying stock.
• Neutral Sentiment: Press coverage summarized 2025 results and clinical progress across Ocugen’s gene‑therapy pipeline — useful for context but not a single clear price catalyst. 2025 results & pipeline update
• Neutral Sentiment: Sector comparison pieces mention Ocugen alongside peers; these can influence sentiment but are not primary drivers of today’s move. Peer performance comparison
• Negative Sentiment: HC Wainwright trimmed several longer‑term EPS forecasts (FY2027–FY2029 and FY2028), reducing some future profitability expectations and highlighting execution/visibility risk beyond 2026. HC Wainwright long‑term estimate cuts

Wall Street Analysts Forecast Growth

Several research analysts recently commented on OCGN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Chardan Capital reissued a “buy” rating and set a $7.00 price target on shares of Ocugen in a research report on Thursday, March 5th. Wall Street Zen lowered shares of Ocugen from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Oppenheimer started coverage on shares of Ocugen in a research report on Wednesday. They issued an “outperform” rating and a $10.00 price objective on the stock. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $8.00.

Institutional Trading of Ocugen

A number of hedge funds have recently modified their holdings of the business. UBS Group AG increased its stake in shares of Ocugen by 373.2% during the fourth quarter. UBS Group AG now owns 4,849,353 shares of the company’s stock valued at $6,547,000 after purchasing an additional 3,824,474 shares in the last quarter. State Street Corp grew its stake in shares of Ocugen by 193.6% in the 4th quarter. State Street Corp now owns 3,978,738 shares of the company’s stock worth $5,371,000 after buying an additional 2,623,361 shares during the last quarter. Marshall Wace LLP bought a new position in Ocugen during the 4th quarter valued at approximately $3,417,000. Goldman Sachs Group Inc. raised its stake in Ocugen by 2,256.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 2,302,475 shares of the company’s stock valued at $3,108,000 after buying an additional 2,204,765 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Ocugen by 485.9% during the fourth quarter. Renaissance Technologies LLC now owns 1,700,400 shares of the company’s stock valued at $2,296,000 after buying an additional 1,410,200 shares during the last quarter. Institutional investors own 10.27% of the company’s stock.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.